Abuse liability assessment of atomoxetine in a drug-abusing population

Drug and Alcohol Dependence

Volumn 95, Issue 1-2, 2008, Pages 140-146

  Jasinski, Donald R ^a   Faries, Douglas E ^b   Moore, Rodney J ^b   Schuh, Leslie M ^b   Allen, Albert J ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

ADHD; Amphetamine; Atomoxetine; Attention deficit hyperactivity disorder; Methylphenidate; Stimulants

Indexed keywords

ATOMOXETINE; DESIPRAMINE; METHYLPHENIDATE; PHENTERMINE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG DOSE COMPARISON; DRUG INDICATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AROUSAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; PAIN MEASUREMENT; PHENTERMINE; PROPYLAMINES; RISK; SUBSTANCE-RELATED DISORDERS;

LAKE VICTORIA MARBURGVIRUS;

EID: 40649122852     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.01.008     Document Type: Article

References (34)

1. Balster R.L., and Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 70 (2003) S13-S40
2. Brauer L.H., Johanson C.-E., Schuster C.R., Rothman R.B., and de Witt H. Evaluation of phentermine and fenfluramine alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology 14 (1996) 233-241
3. Bymaster F.P., Katner J., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., and Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
4. The National Center on Addiction and Substance Abuse (CASA) at Columbia University, 2005. Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S. CASA, New York.
5. Cochran W.G., and Cox G. Experimental Designs (1957), Wiley, New York
6. Cole J.O., Levin A., Beake B., Kaiser P.E., and Scheinbaum M.L. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharm 18 (1998) 231-236
7. Fischman, M.W., Mello, N.K., 1989. Testing for abuse liability of drugs in humans. NIDA Res. Monogr. 92, US DHHS Publication No. (ADM) 89-1613.
8. Foltin R.W., and Fischman M.W. Methods for the assessment of abuse liability of psychomotor stimulants and anorectant agents in humans. Br. J. Addict. 86 (1991) 1633-1640
9. Gasior M., Bergman J., Kallman M.J., and Paronis C.A. Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology 30 (2005) 758-764
10. Griffiths R.R., Bigelow G.E., and Ator N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 70 (2003) S41-S54
11. Heil S.H., Holmes H.W., Bickel W.K., Higgins S.T., Badger G.J., Laws H.F., and Faries D.E. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 67 (2002) 149-156
12. Heishman S.J., and Henningfield J.E. Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. Psychopharmacology (Berl.) 103 (1991) 436-442
13. Jasinski D.R. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J. Psychopharmacol. 14 (2000) 53-60
14. Jasinski D.R., and Henningfield J.E. Human abuse liability assessment by measurement of subjective and physiological effects. NIDA Res. Monogr. 92 (1989) 73-100
15. Jasinski D.R., Pevnick J.S., Griffith J.D., Gorodetsky C.W., and Cone E.J. Progress report on studies from the clinical pharmacology section of the Addiction Research Center. Proceedings of the 38th Meeting Minutes of the Committee on Problems of Drug Dependence. National Research Council, Richmond, VA (1976) 112-148
16. Johanson C.E., and Schuster C.R. A choice procedure for drug reinforcers: cocaine and methylphenidate in the rhesus monkey. J. Pharmacol. Exp. Ther. 193 (1975) 676-688
17. Kleber H.D. Drug abuse liability testing: human subject issues. NIDA Res. Monogr. 92 (1989) 341-356
18. Kleven M.S., Anthony E.W., and Woolverton W.L. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 254 (1990) 312-317
19. Kollins S.H., MacDonald E.K., and Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol. Biochem. Behav. 68 (2001) 611-627
20. Lile J.S., Stoops W.W., Durell T.M., Glaser P.E., and Rush C.R. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp. Clin. Psychopharm. 14 (2006) 136-147
21. Martin W.R., Sloan J.W., Sapira J.D., and Jasinski D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12 (1971) 245-258
22. Molina B.S.G., and Pelham Jr. W.E. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J. Abnorm. Psychol. 112 (2003) 497-507
23. Parran Jr. T.V., and Jasinski D.R. Intravenous methylphenidate abuse Prototype for prescription drug abuse. Arch. Int. Med. 151 (1991) 781-783
24. Risner M.E., and Jones B.E. Self-administration of CNS stimulants by dog. Psychopharmacologia 43 (1975) 207-213
25. Rush C.R., Essman W.D., Simpson C.A., and Baker R.W. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J. Clin. Psychopharmacol. 21 (2001) 273-286
26. Smith R.C., and Davis J.M. Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man. Psychopharmacology (Berl.) 53 (1977) 1-12
27. Spealman R.D. Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. J. Pharmacol. Exp. Ther. 275 (1995) 53-62
28. Spencer T.J., Biederman J., Ciccone P.E., Madras B.K., Dougherty D.D., Bonab A.A., Livni E., Parasrampuria D.A., and Fischman A.J. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatr. 163 (2006) 387-395
29. Stoops W.W., Lile J.A., Glaser P.E., and Rush C.R. Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Exp. Clin. Psychopharmacol. 13 (2005) 56-64
30. Strattera [Package Insert]. Indianapolis, IN, Eli Lilly and Company, 2007.
31. Terry P., Witkin J.M., and Katz J.L. Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine. J. Pharmacol. Exp. Ther. 270 (1994) 1041-1048
32. Wee S., and Woolverton W.L. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend. 75 (2004) 271-276
33. Wilens T.E. The stimulants revisited. Child. Adolesc. Psychiatr. Clin. N. Am. 9 (2000) 573-603
34. Wilson M.C., Hitomi M., and Schuster C.R. Psychomotor stimulant self administration as a function of dosage per injection in the rhesus monkey. Psychopharmacologia 22 (1971) 271-281